Pathophysiological Role of Inflammation in Chronic Diseases

INTRODUCTION

The body's natural reaction to damaging stimuli, such as infections or tissue damage, is inflammation, which is indispensable for both tissue healing and host defence (Cumming & Peters, 2024). The quick, self-limiting progression of acute inflammation is characterised by the conscription of neutrophils with the goal of neutralising the offending substance and fostering healing. On the other hand, chronic inflammation is a maladaptive immune response that lasts a long time and is typified by the continuous activation of mononuclear cells like lymphocytes and macrophages (Al Aloula et al., 2025). In addition to causing tissue damage, this unending inflammation is the root cause of many chronic illnesses, including cancer, diabetes, autoimmune diseases, cardiovascular disease, and neurodegenerative diseases (Siddiqui, 2024).

Pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs) usually cause acute inflammation by exciting the adaptive immune system to reestablish homeostasis (Hollis et al., 2025). However, unresolved acute inflammation or deregulation of immune responses can cause chronic inflammation, which destroys tissue and hastens the course of illness by producing proinflammatory cytokines, chemokines, and immune cell infiltration (Chopra et al., 2024). Chronic inflammation plays a crucial and composite role in the development and course of chronic illnesses by sustaining oxidative stress, genetic damage, and cellular dysfunction (Leyane et al., 2022). Inflammation is a therapeutic target because raised inflammatory markers, such as C-reactive protein (CRP), are prevalent in many chronic illnesses and correspond with higher morbidity and mortality risk (Rizo-Téllez et al., 2023). Consequently, grasping and addressing chronic inflammation is crucial for the effective prevention and treatment of chronic illnesses, and new evidence supports individualised approaches that weigh the advantages and disadvantages of anti-inflammatory treatments (Cacciatore et al., 2025).

Immune Response of the Body and Its Physiological Role

The immune response consists of two interconnected arms: the innate and adaptive immune systems, which operate in an organized manner to defend the body against dangerous infections and tissue impairment (Kiboneka, 2021). The innate immune response is the body's initial line of defence, producing a quick, non-specific response to a wide gamut of pathogens (Lepage & Dubois, 2025). It comprises physical barriers like the skin, biological gears like macrophages, neutrophils, and natural killer cells, and soluble molecules like complement proteins and cytokines (Şenel, 2021). These cells recognise common pathogen-associated molecular patterns (PAMPs) through invariant receptors and respond to curb and slaughter intruders rapidly (Li & Wu, 2021). When the innate immune system fails to eradicate a danger, the adaptive immune system is engaged. This reaction is slower but more specific, involving the activation of lymphocytes, B cells, and T cells, intended to recognise particular antigens given by antigen-presenting cells such as dendritic cells. Adaptive immunity also generates immunological memory, permitting a quicker and more powerful response upon repeated encounters with the same infection (Chi et al., 2024).

Acute to Chronic Inflammation Shift and Its Pathological Consequences

The punch from acute to chronic inflammation emerges when the initial acute inflammatory response fails to eliminate the harmful stimuli, resultant to extended immune activity and persistent tissue damage (Soliman & Barreda, 2022). Acute inflammation is habitually a fleeting process characterised by fluid transudation, leukocyte infiltration (mostly neutrophils), and obstinacy processes that reinstate tissue homeostasis (Harvanova & Durankova, 2025).

Mechanisms of Molecular Pathways

The molecular foundations of chronic inflammation necessitate elaborate interactions among cellular and molecular actors that direct immune responses and tissue homeostasis (Meizlish et al., 2021). Key immune cells comprise macrophages, neutrophils, lymphocytes, and dendritic cells. M1 macrophages yield pro-inflammatory cytokines, including TNF-α, IL-1β, and IL-6, whereas M2 macrophages support tissue repair and resolution (Basheer et al., 2021). The NF-κB, MAPK, and Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathways all play a role in inflammation. NF-κB regulates pro-inflammatory gene transcription, MAPK responds to straining and cytokines, and JAK-STAT regulates cytokine signalling (Kannan et al., 2025). Instigation of these pathways stimulates the consolidation of chemokines and cytokines, which recruit more immune cells and prolong inflammation. Immune cell conscription is facilitated by chemokines like monocyte chemoattractant protein-1 (MCP-1/CCL2), while transcription factors like NF-κB regulate the production of inflammatory mediators and cell endurance proteins, such as the BCL-2 family. Dysregulation of these pathways recompences the balance of pro-inflammatory and anti-inflammatory signals, resulting in chronic inflammation and tissue damage (Kubatka et al., 2021). Chronic inflammation is initiated by immune cell activation and molecular pathways, including NF-κB, MAPK, and JAK-STAT. These pathways integrate indications from cytokines and chemokines, momentous in obstinate inflammation and contributive to chronic disease etiology (Kapoor et al., 2025).

Etiology and Risk Factors

Chronic inflammation is caused by a composite interaction of etiological origins and risk contributors, including chronic infections, environmental exposures, lifestyle habits, and primary immunological dysregulation (Ramos-Lopez et al., 2021). Communal reasons include the inability to eliminate infectious organisms such as Mycobacterium tuberculosis, fungi, or parasites that defy immune defence, resulting in chronic inflammation (Chandra et al., 2022). Moreover, continued exposure to irritants or toxic substances such as silica dust or industrial chemicals can initiate chronic inflammatory responses because they are resistant to enzymatic breakdown or clearance (Nikpour et al., 2025). An additional chief cause of persistent inflammation is autoimmune illnesses, which arise when the immune system mistakenly assaults normal tissues, such as rheumatoid arthritis and systemic lupus erythematosus. Auto-inflammatory syndromes are an example of how genetic or cellular anomalies in inflammation regulation pathways might contribute (Rose, 2022). Lifestyle and environmental risk factors are significant contributors. Diets heavy in processed foods, saturated fats, and sweets, physical inactivity, obesity, smoking, excessive alcohol use, persistent psychological stress, and unbalanced sleep patterns increase systemic low-grade inflammation associated with the expansion of chronic diseases (Cifuentes et al., 2025).

Environmental Lifestyle and Infectious Triggers

Environmental, behavioral, and viral factors all play substantial roles in the development and progression of chronic inflammation. Environmental variables comprise exposure to pollutants such as airborne particulate matter, nitrogen oxides, sulphur oxides, volatile organic compounds, and industrial chemicals encountered in industrial surroundings (Fazakas et al., 2024). Pollutants cause oxidative stress by generating reactive oxygen species (ROS), which initiate inflammatory pathways such as NF-κB and MAPK. This leads to innate immune activation and chronic inflammation (D'Souza et al., 2024). Lifestyle factors such as poor nutrition, rich in processed foods and sweets, physical inactivity, smoking, excessive alcohol use, persistent psychological stress, and irregular sleep patterns contribute to a pro-inflammatory ailment (Kip & Parr-Brownlie, 2023). Obesity, recurrently caused by poor lifestyles, is a primary source of systemic low-grade inflammation because extra adipose tissue releases inflammatory cytokines (Khanna et al., 2022). Infectious triggers are chronic bacterial, viral, fungal, or parasitic infections that the immune system fails to clear entirely, resulting in continual immunological stimulation and tissue damage (Cumming & Peters, 2024).

Influence of Diet, Physical Activity, and Social Determinants of Health

Diet, physical exercise, and social elements of health have a foremost effect on chronic inflammation through a variety of physiological and behavioral pathways (Ramos-Lopez et al., 2021). Western diets high in processed foods, saturated fats, sweets, and refined carbohydrates can trigger inflammation by activating immunological pathways such as NF-κB, boosting pro-inflammatory cytokines like TNF-α and IL-6, and leading to insulin resistance and oxidative stress (Malesza et al., 2021). Anti-inflammatory diets, such as the Mediterranean diet, which is high in fruits, vegetables, whole grains, omega-3 fatty acids, and antioxidants, have been proven to lower systemic inflammation gauges and positively modify gene expression (Mukherjee et al., 2023). Physical inactivity causes chronic inflammation by encouraging visceral fat storage, which stows inflammatory mediators, whereas regular exercise has anti-inflammatory benefits by lowering adiposity, enhancing insulin sensitivity, and amending immune cell function (Verdu et al., 2021). Social factors of health, such as socioeconomic status, education, stress levels, and access to healthcare and healthy meals, influence lifestyle behaviors and exposure to environmental stressors, affecting inflammation (Coppi et al., 2024). Chronic psychosocial stress arouses the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system, advancing circulating inflammatory cytokines and sustaining inflammatory states (Tsigos & Chrousos, 2002).

Chronic Inflammation and Disease Pathogenesis

Chronic inflammation contributes to disease aetiology by perpetuating the sequence of immune activation, tissue damage, and repair, which ultimately leads to organ failure and disease development (Gusev & Zhuravleva, 2022). The shift from acute to chronic inflammation includes the lingering presence of harmful stimuli or failure of firmness processes, terminating in the recruitment and activation of macrophages, lymphocytes, and plasma cells in the inundated tissues (Soliman & Barreda, 2022). Inflammatory mediators such as IL-1β, IL-6, TNF-α, and chemokines stimulate immune cell intrusion and produce reactive oxygen species and proteolytic enzymes, resulting in tissue damage and remodeling. Signalling pathways such as NF-κB, MAPK, and JAK-STAT influence gene expression of pro- and anti-inflammatory molecules (Purohit et al., 2023). Chronic inflammation has been connected to several illnesses, including atherosclerosis, diabetes, rheumatoid arthritis, neurological disorders, and cancer (Leyane et al., 2022). It promotes fibrosis, granuloma development, and commotion of regular tissue architecture, all of which contribute to functional impairment and progression of these disorders (Antar et al., 2023).

How Chronic Inflammation Contributes to Disease Development and Progression

Chronic inflammation contributes to disease genesis and progression by persistently activating the immune system, causing continuing tissue damage and remodeling (Gusev & Zhuravleva, 2022). Originally, acute inflammation strives to remove damaging stimuli and rectify tissue, but when vague, a persistent immune response occurs, characterised by infiltration of macrophages, lymphocytes, and plasma cells at the location of damage (Soliman & Barreda, 2022). Inflammatory cytokines like IL-1β, IL-6, and TNF-α cause inflammation by attracting immune cells and producing reactive oxygen species and proteolytic enzymes that harm surrounding tissues (Muzamil et al., 2021). Pro-inflammatory genes are delimited by key signalling pathways, including NF-κB, MAPK, and JAK-STAT, which sustain an inflammatory milieu (Haftcheshmeh et al., 2023). This tenacious immune activation persuades morphological and functional tissue amendments, including fibrosis, necrosis, and granuloma development, which compromise normal organ function (Antar et al., 2023). These pathogenic progressions are essential to the course of many chronic illnesses, including atherosclerosis, diabetes, rheumatoid arthritis, neurological disorders, and cancer (Gusev & Zhuravleva, 2022).

Major Chronic Diseases Associated with Inflammation

Foremost chronic illnesses related to inflammation embrace a wide range of disorders in which persistent immunological activation and tissue damage play critical roles. This includes:

Cardiovascular diseases

Atherosclerosis is a chronic inflammatory disease of the artery wall characterised by the accretion of plaques entailing lipids, cholesterol, immune cells, and fibrous materials (Gusev & Sarapultsev, 2023). The condition begins with endothelial damage instigated by risk factors such as oxidised low-density lipoprotein (oxLDL), high glucose levels, and smoking, which leads to endothelial dysfunction and augmented production of adhesion molecules such as VCAM-1 and ICAM-1 (Jiang et al., 2022). These adhesion molecules fascinate circulating monocytes and T lymphocytes to the artery intima (Watanabe & Fan, 2025). Monocytes develop into macrophages, which engross oxLDL and form foam cells, a characteristic of atherosclerotic plaques. Foam cells and activated immune cells produce pro-inflammatory cytokines (e.g., IL-1β, TNF-α, IL-6) and reactive oxygen species, leading to local inflammation, recruitment of additional immune cells, smooth muscle cell proliferation, and extracellular matrix deposition. These mechanisms endorse plaque development, fibrosis, and finally plaque dislocation (Gui et al., 2022).

Metabolic disarrays

Chronic inflammation plays a treacherous role in the etiology of metabolic illnesses enumerating obesity and type 2 diabetes (Rohm et al., 2022). Obesity is prompted by spare adipose tissue, particularly visceral fat, which secretes pro-inflammatory cytokines such as IL-6, TNF-α, and leptin. These intermediaries stimulate the draught and instigation of immune cells, chiefly macrophages with a pro-inflammatory M1 phenotype, creating an obstinate low-grade inflammatory milieu in adipose tissue (Henning, 2021). Inflammation can cause pancreatic β-cell malfunction and death, leading to poor glucose homeostasis (Dludla et al., 2023). Chronic inflammation disrupts insulin signalling pathways, activating stress kinases (e.g., JNK, IKKβ) and interfering with insulin receptor function. This leads to insulin resistance, an ultimate characteristic of type 2 diabetes (Szukiewicz, 2023). This systemic inflammatory condition also disturbs other organs, including the liver and skeletal muscle, resulting in metabolic dysregulation. Inflammation-induced oxidative stress and cellular damage deteriorate metabolic syndrome components such as hypertension and dyslipidemias, increasing cardiovascular risk (Nzobokela et al., 2025). Inclusively, chronic inflammation is mutually an origin and a symptom of metabolic diseases, resulting in a vicious cycle that perpetuates and aggravates disease progression.

Autoimmune diseases

Autoimmune illnesses, such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), are characterised by persistent inflammation caused by the immune system's inability to discriminate self from non-self, resulting in immune-mediated tissue annihilation (Xiang et al., 2023). In this status quo, innate immune cells (e.g., neutrophils, macrophages, dendritic cells) generate inflammatory cytokines, including TNF-α, IL-1β, and IL-6, driving local tissue damage and drafting adaptive immunity cells, including autoreactive T and B lymphocytes (Sierawska et al., 2022). In RA, neutrophils arrive at joints, causing cartilage breakdown, and dendritic cells stimulate T-cells that develop into pro-inflammatory subdivisions (Th1, Th17), secreting cytokines that exaggerate inflammation and B-cell autoantibody production. This leads to extended synovial inflammation, joint degeneration, and discomfort (Wen & Liu, 2025). Chronic gastrointestinal inflammation in IBD is triggered by an imbalance of effector and regulatory T-cells, resulting in epithelial cell demolition and mucosal barrier breakdown. Cytokines like interferon-gamma and IL-17 increase the inflammatory response, prolonging disease activity and fibrosis (Barbara et al., 2021). Genetic penchant, environmental triggers, and immune regulatory deficits all contribute to disease etiology by keeping chronic inflammation. Treatments targeting cytokines (e.g., anti-TNF drugs) have demonstrated success in stopping these inflammatory pathways (Xiang et al., 2023).

Neurodegenerative diseases

Alzheimer's disease (AD) and Parkinson's disease (PD) are illustrations of neurodegenerative disorders that entail chronic neuroinflammation caused by the continuous activation of microglia and astrocytes, the brain's resident immune cells. When galvanized, microglia emit pro-inflammatory cytokines such as IL-1β, TNF-α, and reactive oxygen/nitrogen species, leading to neuronal damage and disseminating the damaging inflammatory cycle (Wendimu & Hooks, 2022). During neuroinflammation, the blood-brain barrier (BBB) breaks down, aiding peripheral immune cells like T-cells and macrophages to assault the CNS and increase inflammatory reactions. Toll-like receptors (TLRs) on microglia recognise accumulated proteins such as amyloid-beta plaques in AD and alpha-synuclein in PD, initiating innate immune activation and chronic inflammation (Huang et al., 2021). Chronic neuroinflammation disrupts neuronal homeostasis, increases tau hyperphosphorylation, excitotoxicity, and synaptic dysfunction, resulting in progressive cognitive decline, motor disability, and neurodegeneration. Failure to reduce the inflammation adds noticeably to disease development and severity (Zhang et al., 2023). Neuroinflammation targeting is emerging as an important therapeutic option for slowing or discontinuing the course of neurodegenerative diseases.

Cancer

Chronic inflammation is a well-known promoter of cancer growth and progression because it generates a tumor-promoting milieu. Inflammatory signals activate pathways including NF-κB, STAT3, and HIF-1α, resulting in increased production of cytokines (e.g., TNF-α, IL-1β, IL-6), chemokines, and enzymes like COX-2 and iNOS that augment cell proliferation, survival, angiogenesis, and metastasis (Cao et al., 2024). Oxidative stress caused by inflammation damages DNA and disrupts the genome, allowing oncogenic mutations to occur. Tumor-associated macrophages (TAMs), myeloid-derived suppressor cells, and cancer-associated fibroblasts enter the tumor microenvironment and stow molecules that impede efficient anti-tumor immunity while endorsing tumor development and incursion. Additionally, continuous inflammation can be a root cause of immunosuppressive mechanisms, such as PD-L1 expression, especially on tumor cells, which allows immune dodging (Rembiałkowska et al., 2025). This pro-tumorigenic inflammation arises at all stages of cancer, from initiation to metastasis, and determines treatment response. As a result, merging standard cancer therapy with anti-inflammatory drugs has potential for improving patient outcomes.

Therapeutic Approaches and Management

The treatment to accomplish chronic inflammation, firstly, we should focus on minimising inflammatory triggers, which are raised by immunological responses, and ultimately, it will slow the disease severity. Some of the key tactics are described below;

Pharmacological intrusions: Pharmacologic inventions play a huge role in dealing with chronic inflammation in numerous diseases, with treatments targeting different pathways and mechanisms to decrease or entirely obliterate inflammation, control symptoms, and prevent disease progression Table 1.

Nutritional and lifestyle modifications: Nutrition and modifications are very important and critical components in managing chronic inflammation and taming overall health outcomes.

Anti-Inflammatory Diet Adaptations: The diet plan, according to the anti-inflammatory sequence, for example, emphasises the eating of fruits, vegetables, whole grains, nuts, beans, omega-3 fatty acid-rich seafood, and healthy fats such as olive oil, and some types of anti-inflammatory teas. These foods are high in antioxidants, polyphenols, and fiber, which lower pro-inflammatory cytokines (e.g., IL-6, CRP) and oxidative stress (Dobroslavska et al., 2024). Eating processed meals, refined sugars, saturated fats, and red meats helps to diminish systemic inflammation. Studies have unswervingly shown that these diets enhance endothelial function, insulin sensitivity, and lower levels of chronic inflammation in illnesses such as cardiovascular disease, type 2 diabetes, and autoimmune disorders (Giugliano et al., 2006).

Physical Activity: Regular moderate exercise lowers inflammatory indicators via reducing visceral fat, increasing antioxidant defence, and boosting immunological intonation (Antinozzi et al., 2025). Exercise rallies metabolic and cardiovascular health by curbing anti-inflammatory cytokines such as IL-10 and lowering TNF-α levels (Guo et al., 2024).

Stress Reduction: Chronic psychological stress activates inflammatory pathways via the hypothalamic-pituitary-adrenal axis and sympathetic nervous system, elevating cortisol and catecholamine levels, which puzzlingly increase inflammation when exposed for an extended period of time. Mindfulness, meditation, yoga, and appropriate sleep can help lower this neuroendocrine-mediated inflammation, which improves immune function and disease outcomes (Knezevic et al., 2023). Mutually, all the variations in lifestyle approaches act as fundamental, complementary therapies to pharmaceutical treatments for efficiently managing chronic inflammatory disorders.

Herbal and Natural Therapy’s Role

If herbal and natural remedies are a major part of our life it can manage chronic inflammation by altering immunological responses, suppressing oxidative stress, and downregulating inflammatory pathways on a molecular level. Generally, deliberate herbs and natural compounds are given in Table 2.

While these herbal suppositories typically have promising safety profiles because their Side effects are not like pharmacological medicines, they should be used as supplementary treatments under medical supervision to decrease interactions and ensure optimal dose. Like traditions chines medicines and Indian herbal treatment are very popular worldwide (Hassen et al., 2022). Emergent research continues to explore their molecular mechanisms and therapeutic potential.

FUTURE DIRECTIONS FOR EMERGING THERAPIES

Emerging medicines treatment and future inventions through research in chronic inflammation control are centered and focusing on precisely modulating immune responses, refining targeting, and minimising contrary effects by using these medications (Strzelec et al., 2023). The following methods are under observation:

Dapansutrile, a small chemical, explicitly inhibits the NLRP3 inflammasome, which is mainly responsible for producing IL-1β and initiating sterile inflammation in early pathogen or injury response. Early-phase trials of this chemical show amazing result in heart failure and cardiovascular disorders by lowering systemic inflammation while continuing favorable safety profiles with minimum side effects compared to previous medicines (Del Buono et al., 2021). RNA-Based Therapies like Small Interfering RNA (siRNA) and antisense oligonucleotides are two practices that trigger some pathways that are very important for the downregulation of inflammatory mediators and pathogenic proteins. siRNA therapeutics targeting transthyretin in amyloidosis have been approved, and continuing trials are extending their applicability and have not get that much effective results (Keller et al., 2025). Monoclonal antibodies and biologics, which directly target cytokines such as IL-6, IL-1β, and chemokines that are the main cause of inflammation and signal nearby cells to trigger the same responses, are being developed for clinical use. Combination medicines try to balance immune conquest with maintaining host defence (Yi et al., 2024). Nanotechnology and Drug Conveyance. Such nanoparticle-based delivery approaches boost bioavailability, enable precise release, and evade biological fences such as the blood-brain barrier, increasing therapeutic reach to neuroinflammatory illnesses (Susa et al., 2024). CRISPR-Cas9 gene deletion has the potential to fix gene mutations and judicious immunological pathways that cause chronic inflammation. Nevertheless, clinical translation is tranquil in the early stages and still needs to be observed deeply (Romano & Mortellaro, 2024). Lifestyle-integrated Meticulousness Medicine syndicates genetic, environmental, and lifestyle variables to optimise pharmacologic and non-pharmacologic interventions. Communally, these novel techniques are anticipated to alter chronic inflammation therapy by cumulative effectiveness, reducing side effects, and tailoring treatment to specific patient profiles.

CHALLENGES AND FUTURE PROSPECTS

The obscurity and dismissal of inflammatory pathways provide challenges in chronic inflammation treatment, preventing the efficiency of targeted therapy and increasing the risk of immune suppression and contrary effects. Many chronic inflammatory illnesses have no cure and rely on symptomatic therapy, making long-term disease management problematic. Patient variability, comorbidities, and fluctuating reactions to pharmacological and nonpharmacological therapy all thwart management. Prospects focus on unified, personalised medical techniques that syndicate innovative biomarkers for real-time inflammatory monitoring, precision-targeted suppositories (such as NLRP3 inhibitors and RNA treatments), and enhanced drug delivery technologies like nanotechnology. Indorsing endogenous resolution pathways with specialised pro-resolving mediators constitutes a prototype change from suppression to tissue homeostasis. Active lifestyle, interactive therapy, and positive social interactions alongside medication address the many causes of chronic inflammation and help to manage our hormonal levels positively. Interdisciplinary research programs, such as phase 2 of Canada's Health Challenges in Chronic Inflammation, emphasise collaborative, translational research and patient involvement in order to speed discovery and optimise management solutions. Technologies such as bioelectronic medicine and gene editing have even more potential, but they require inclusive validation and a very high budget. Finally, solving problems requires a systems biology slant that integrates molecular, clinical, behavioral, and social variable quantity to design effective therapies and augment global results in somehow in affordable way.

CONCLUSION

Chronic inflammation is a major cause of many chronic illnesses, including cardiovascular, metabolic, autoimmune, neurodegenerative, and malignant disorders, and it is the largest cause of morbidity and mortality worldwide, a silent killer behind major diseases. A thorough knowledge of molecular pathways, including immune cell activation, cytokine networks, oxidative stress, and dysregulated resolution mechanisms, has provided crucial insights into disease pathophysiology and revealed novel treatment targets. This chapter provides a basic resource that elucidates the pathophysiological function of inflammation in continuing illnesses, existing treatment archetypes, and promising future throughfares for minimising the worldwide burden of these rife ailments.